General Session
Advances in Precision Therapy in CLL: Integrating BTK and BCL-2 Inhibition Across the Treatment Continuum
45 min
Friday, October 16, 2026
8:50 AM - 9:35 AM
Supported by educational grants from AstraZeneca and BeOne.
-
Speaker
-
John Allan MD -
Andrew Zelenetz MD, PhD
-
-
Room
- Broadway South